AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24135530 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-186 (edaravone) with a loading dose of 0.08 mg/kg + 0.2 mg/kg/h infusion
Number of subjects: 54
Study 24135530 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-186 (edaravone) with a loading dose of 0.16 mg/kg + 0.4 mg/kg/h infusion
Number of subjects: 54
Study 24135530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 20954761 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families program
Number of subjects: 337
Study 20954761 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 337
Study 18239552 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated:unsaturated fat (SFA:USFA) diet
Number of subjects: 18
Study 18239552 — intervention group
Group type: COMPARATOR
Intervention: Lower SFA:USFA diet
Number of subjects: 18
Study 16980316 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (10 individualised treatments)
Number of subjects: 241
Study 16980316 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 241
Study 15295414 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate atherosclerosis (CAC score of 100-400 Agatston units)
Number of subjects: 220
Study 15295414 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe atherosclerosis (CAC score > or =400 Agatston units)
Number of subjects: 220
Study 15295414 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing severity of atherosclerosis
Number of subjects: 220
Study 11518437 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise programme (regular group exercises and home exercises for a period of three months)
Number of subjects: 47
Study 9253568 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoethylglycinexylidide synthesis
Number of subjects: 71
Study 9253568 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V index (FVI)
Number of subjects: 71
Study 9253568 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin time index (PTI)
Number of subjects: 71
Study 9253568 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma bilirubin
Number of subjects: 71
Study 9253568 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase (ASAT)
Number of subjects: 71
Study 9253568 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase (ALAT)
Number of subjects: 71
Study 8433884 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose with amino acids (1.5 g.kg‐1.d‐1) i.v.
Number of subjects: 23
Study 8433884 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 23
Study 3127815 — intervention group
Group type: EXPERIMENTAL
Intervention: doxycycline 0.1 g x 2
Number of subjects: 8
Study 3127815 — intervention group
Group type: EXPERIMENTAL
Intervention: demethylchlortetracycline (DMCT) 0.3 g x 2
Number of subjects: 8
Study 3127815 — intervention group
Group type: EXPERIMENTAL
Intervention: lymecycline 0.6 g x 2
Number of subjects: 8
Study 3127815 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 31166214 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 12
Study 31166214 — intervention group
Group type: COMPARATOR
Intervention: Steroids and other immunosuppressants (concurrently treated)
Number of subjects: 12
Study 29979644 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 78
Study 29979644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 27716283 — intervention group
Group type: EXPERIMENTAL
Intervention: U-500R TID (n=162)
Number of subjects: 325
Study 27716283 — intervention group
Group type: EXPERIMENTAL
Intervention: U-500R BID (n=163)
Number of subjects: 325
Study 27716283 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 325
Study 25091192 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular resonance (MR)
Number of subjects: 873
Study 25091192 — intervention group
Group type: COMPARATOR
Intervention: Cold-knife (CK)
Number of subjects: 873
Study 25091192 — intervention group
Group type: COMPARATOR
Intervention: Monopolar cautery (MPC)
Number of subjects: 873
Study 22303845 — intervention group
Group type: EXPERIMENTAL
Intervention: Predator urine
Number of subjects: 56
Study 22303845 — intervention group
Group type: COMPARATOR
Intervention: Non-predator urine
Number of subjects: 56
Study 22303845 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 56
Study 22303845 — intervention group
Group type: EXPERIMENTAL
Intervention: Defensive behaviors (vigilance and fleeing)
Number of subjects: 56
Study 20303833 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 60
Study 20303833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 60
Study 20303833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VCV and PCV
Number of subjects: 60
Study 18394765 — intervention group
Group type: EXPERIMENTAL
Intervention: MV and LJEV together at 9 months (Group 2)
Number of subjects: 571
Study 18394765 — intervention group
Group type: COMPARATOR
Intervention: MV and LJEV at 9 and 10 months, respectively (Group 3)
Number of subjects: 571
Study 18394765 — intervention group
Group type: COMPARATOR
Intervention: LJEV administered at age of 8 months and MV at 9 months (Group 1)
Number of subjects: 571
Study 18394765 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Group 1, Group 2, Group 3)
Number of subjects: 571
Study 15933423 — intervention group
Group type: EXPERIMENTAL
Intervention: edrecolomab (900 mg total)
Number of subjects: 377
Study 15933423 — intervention group
Group type: COMPARATOR
Intervention: observation
Number of subjects: 377
Study 12908073 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 50
Study 12908073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10571605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg once daily
Number of subjects: 396
Study 10571605 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 396
Study 8561641 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-treated group (St. Thomas' Hospital cardioplegic solution No. 1 plus CP 10 mmol/L)
Number of subjects: 50
Study 8561641 — intervention group
Group type: COMPARATOR
Intervention: Control group (St. Thomas' Hospital cardioplegic solution No. 1)
Number of subjects: 50
Study 1871547 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime UDCA 7 mg/kg/day
Number of subjects: 44
Study 1871547 — intervention group
Group type: COMPARATOR
Intervention: Mealtime UDCA 10 mg/kg/day
Number of subjects: 44
Study 1871547 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime UDCA (average minimum effective dose) 8.4 mg/kg/day
Number of subjects: 44
Study 1871547 — intervention group
Group type: COMPARATOR
Intervention: Repeated-release tablet formulation of UDCA
Number of subjects: 44
Study 6221200 — intervention group
Group type: EXPERIMENTAL
Intervention: THIP (4,5,6,7‐tetrahydroisoxazolo‐[5,4,‐c] pyridin‐3‐ol) administered orally for 2 weeks
Number of subjects: 5
Study 6221200 — intervention group
Group type: EXPERIMENTAL
Intervention: THIP (4,5,6,7‐tetrahydroisoxazolo‐[5,4,‐c] pyridin‐3‐ol) at maximum levels
Number of subjects: 5
Study 6221200 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose THIP therapy
Number of subjects: 5
Study 30059193 — intervention group
Group type: COMPARATOR
Intervention: AAA tablet
Number of subjects: 45
Study 30059193 — intervention group
Group type: COMPARATOR
Intervention: NXA tablet
Number of subjects: 45
Study 30059193 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tablet formulations
Number of subjects: 45
Study 30558053 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg/day)
Number of subjects: 53
Study 30558053 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 53
Study 27071386 — intervention group
Group type: COMPARATOR
Intervention: EUS‐FNA (22G EchoTip Ultra needle)
Number of subjects: 408
Study 27071386 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐FNB (22G EchoTip ProCore needle)
Number of subjects: 408
Study 25722177 — intervention group
Group type: EXPERIMENTAL
Intervention: PMCT-10min test
Number of subjects: 49
Study 25722177 — intervention group
Group type: EXPERIMENTAL
Intervention: PMCT-2min test
Number of subjects: 49
Study 25722177 — intervention group
Group type: COMPARATOR
Intervention: Younger participants
Number of subjects: 49
Study 25722177 — intervention group
Group type: EXPERIMENTAL
Intervention: Older participants
Number of subjects: 49
Study 23295878 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate + amodiaquine
Number of subjects: 210
Study 23295878 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 210
Study 20938357 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training group (PG)
Number of subjects: 27
Study 20938357 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded plyometric group (LPG, weighted vests 10-11% body mass)
Number of subjects: 27
Study 20938357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no plyometric training)
Number of subjects: 27
Study 18580553 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 624
Study 18580553 — intervention group
Group type: COMPARATOR
Intervention: Continuation ECT
Number of subjects: 624
Study 18580553 — intervention group
Group type: COMPARATOR
Intervention: Continuation pharmacotherapy
Number of subjects: 624
Study 16213233 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-enhanced exercise protocol
Number of subjects: 32
Study 16213233 — intervention group
Group type: COMPARATOR
Intervention: Non-VR group (control)
Number of subjects: 32
Study 11791829 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at Home
Number of subjects: 199
Study 11791829 — intervention group
Group type: COMPARATOR
Intervention: Hospital
Number of subjects: 199
Study 10527974 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal fertile women
Number of subjects: 53
Study 10527974 — intervention group
Group type: COMPARATOR
Intervention: Women with unexplained infertility
Number of subjects: 53
Study 8742775 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and pharmacological treatment (specifics not available)
Number of subjects: 0
Study 8742775 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (e.g., Dual Diagnosis Relapse Prevention treatment with desipramine)
Number of subjects: 0
Study 8742775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment of anxiety, mood, and psychotic disorders
Number of subjects: 0
Study 8742775 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific psychosocial treatment techniques for subgroups of dually diagnosed patients
Number of subjects: 0
Study 2032103 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultant assessment
Number of subjects: 38
Study 2032103 — intervention group
Group type: EXPERIMENTAL
Intervention: Research fellow assessment
Number of subjects: 38
Study 2032103 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal endosonography (initial criteria)
Number of subjects: 38
Study 2032103 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal endosonography (revised criteria)
Number of subjects: 38
Study 2032103 — intervention group
Group type: COMPARATOR
Intervention: Consultant assessment vs Anal endosonography
Number of subjects: 38
Study 2032103 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultant assessment of secondary supralevator and infralevator tracks
Number of subjects: 38
Study 6383116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1% with adrenaline 1:100,000
Number of subjects: 0
Study 6383116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1%
Number of subjects: 0
Study 6383116 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine 1%
Number of subjects: 0
Study 6383116 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 0
Study 31032904 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit sent directly
Number of subjects: 8000
Study 31032904 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to order a HPV self-sampling kit using a new open source eHealth web application
Number of subjects: 8000
Study 31032904 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to call a coordinating midwife with questions and concerns
Number of subjects: 8000
Study 31032904 — intervention group
Group type: COMPARATOR
Intervention: Standard annual renewed invitation letter with prebooked appointment time (routine practice)
Number of subjects: 8000
Study 30003459 — intervention group
Group type: EXPERIMENTAL
Intervention: Links to publicly accessible online prevention content via email
Number of subjects: 60
Study 30003459 — intervention group
Group type: COMPARATOR
Intervention: Control group (no internet content received)
Number of subjects: 60
Study 26554884 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 1,000 IU/day/orally (n = 80)
Number of subjects: 160
Study 26554884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 80)
Number of subjects: 160
Study 25458024 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 36
Study 25458024 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure (sham acupuncture)
Number of subjects: 36
Study 22158728 — intervention group
Group type: COMPARATOR
Intervention: Exposure + tangible reward (sticker)
Number of subjects: 173
Study 22158728 — intervention group
Group type: COMPARATOR
Intervention: Exposure + social reward (praise)
Number of subjects: 173
Study 22158728 — intervention group
Group type: EXPERIMENTAL
Intervention: No-treatment control
Number of subjects: 173
Study 20378684 — intervention group
Group type: EXPERIMENTAL
Intervention: vodka
Number of subjects: 45
Study 20378684 — intervention group
Group type: EXPERIMENTAL
Intervention: white wine
Number of subjects: 45
Study 20378684 — intervention group
Group type: EXPERIMENTAL
Intervention: red wine
Number of subjects: 45
Study 20378684 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 45
Study 21974759 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ 160/12.5 mg
Number of subjects: 384
Study 21974759 — intervention group
Group type: COMPARATOR
Intervention: valsartan 160 mg
Number of subjects: 384
Study 21974759 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 12.5 mg
Number of subjects: 384
Study 21974759 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ
Number of subjects: 384
Study 21974759 — intervention group
Group type: COMPARATOR
Intervention: HCTZ
Number of subjects: 384
Study 21974759 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 384
Study 16081882 — intervention group
Group type: EXPERIMENTAL
Intervention: G773D variant in elastin
Number of subjects: 0
Study 12659404 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/EE (Yasmin)
Number of subjects: 22
Study 12659404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9756050 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment compliance
Number of subjects: 0
Study 9756050 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at therapy sessions
Number of subjects: 0
Study 8056129 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice a day)
Number of subjects: 10
Study 3382038 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.67 mg/kg with atropine doses ranging from 0.0125 to 0.0215 mg/kg (group A, n = 37)
Number of subjects: 72
Study 3382038 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg/kg with atropine doses ranging from 0.02 to 0.04 mg/kg (group B, n = 35)
Number of subjects: 72
Study 29304907 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural frequencies
Number of subjects: 14
Study 29304907 — intervention group
Group type: COMPARATOR
Intervention: Conditional probabilities
Number of subjects: 14
Study 26712409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of diluted tincture of opium (DTO)
Number of subjects: 0
Study 26712409 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model for morphine after oral administration of DTO
Number of subjects: 0
Study 26715594 — intervention group
Group type: EXPERIMENTAL
Intervention: HUAREN peritoneal dialysis fluid (packed in non-PVC bags)
Number of subjects: 0
Study 26715594 — intervention group
Group type: COMPARATOR
Intervention: Baxter peritoneal dialysis fluid (packed in PVC bags)
Number of subjects: 0
Study 26715594 — intervention group
Group type: EXPERIMENTAL
Intervention: HUAREN peritoneal dialysis fluid
Number of subjects: 0
Study 26715594 — intervention group
Group type: COMPARATOR
Intervention: Baxter peritoneal dialysis fluid
Number of subjects: 0
Study 23623449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 58
Study 23623449 — intervention group
Group type: COMPARATOR
Intervention: Enriched Supportive Therapy (EST)
Number of subjects: 58
Study 20805597 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min psychomotor vigilance task (PVT) in an isolated setting
Number of subjects: 75
Study 20805597 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min psychomotor vigilance task (PVT) in a classroom setting
Number of subjects: 75
Study 20805597 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min psychomotor vigilance task (PVT) in an isolated setting conducted second
Number of subjects: 75
Study 20805597 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min psychomotor vigilance task (PVT) in both settings
Number of subjects: 75
Study 18199300 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention (DL)
Number of subjects: 261
Study 18199300 — intervention group
Group type: COMPARATOR
Intervention: Control group (PBA)
Number of subjects: 261
Study 16179215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg once daily
Number of subjects: 653
Study 16179215 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 mcg twice daily
Number of subjects: 653
Study 12544410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (part of dual nucleoside reverse transcriptase inhibitor therapy)
Number of subjects: 108
Study 12544410 — intervention group
Group type: EXPERIMENTAL
Intervention: Full adherence to prescribed medication
Number of subjects: 108
Study 12544410 — intervention group
Group type: COMPARATOR
Intervention: Full adherence vs. some nonadherence
Number of subjects: 108
Study 10744780 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% fat, 75% carbohydrate diet
Number of subjects: 19
Study 10744780 — intervention group
Group type: COMPARATOR
Intervention: 30% fat, 55% carbohydrate diet
Number of subjects: 19
Study 10744780 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% fat diet
Number of subjects: 19
Study 10744780 — intervention group
Group type: COMPARATOR
Intervention: 30% fat diet
Number of subjects: 19
Study 8898461 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated control measures including health education, sanitation, environmental management, and chemotherapy
Number of subjects: 600
Study 8898461 — intervention group
Group type: EXPERIMENTAL
Intervention: Snail intermediate host control measures
Number of subjects: 600
Study 1500694 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha lymphoblastoid interferon plus acyclovir
Number of subjects: 97
Study 1500694 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 97
Study 6146414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 17
Study 6146414 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets twice daily
Number of subjects: 17
Study 31125735 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening for GGOs 4 to 5 mm (0.4% malignancy risk)
Number of subjects: 0
Study 31125735 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month follow-up for GGOs 6 to 7 mm (1.1%)
Number of subjects: 0
Study 31125735 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month follow-up for GGOs 8 to 14 mm (3.0%)
Number of subjects: 0
Study 31125735 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month follow-up for GGOs 15 to 19 mm (5.2%)
Number of subjects: 0
Study 31125735 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month follow-up for GGOs greater than or equal to 20 mm (10.9%)
Number of subjects: 0
Study 31125735 — intervention group
Group type: COMPARATOR
Intervention: GGOs versus solid nodules for lung-cancer death
Number of subjects: 0
Study 29377893 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-circuit training (SCT)
Number of subjects: 29
Study 29377893 — intervention group
Group type: COMPARATOR
Intervention: Continuous aerobic training (CAT)
Number of subjects: 29
Study 26868317 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (laparoscopy followed by arthroscopy)
Number of subjects: 72
Study 26868317 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (arthroscopy followed by laparoscopy)
Number of subjects: 72
Study 26868317 — intervention group
Group type: COMPARATOR
Intervention: Control group (laparoscopic cholecystectomy)
Number of subjects: 72
Study 26868317 — intervention group
Group type: COMPARATOR
Intervention: Control group (diagnostic knee arthroscopy)
Number of subjects: 72
Study 26868317 — intervention group
Group type: EXPERIMENTAL
Intervention: All cohorts
Number of subjects: 72
Study 23882088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 48
Study 23882088 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 48
Study 23882088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23882088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, Acetaminophen, Placebo
Number of subjects: 48
Study 22914036 — intervention group
Group type: EXPERIMENTAL
Intervention: polihexanide 0.02%
Number of subjects: 20
Study 22914036 — intervention group
Group type: EXPERIMENTAL
Intervention: polihexanide 0.04%
Number of subjects: 20
Study 22914036 — intervention group
Group type: COMPARATOR
Intervention: chlorhexidine 0.05%
Number of subjects: 20
Study 20581724 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg for 5 weeks
Number of subjects: 53
Study 20581724 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 53